Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Who has to pay?

How NHS overseas visitors charges apply to migrants and asylum seekers in England.

Published
11 hours ago
From
NAT
HIV-positive youth are less likely than adults to achieve viral suppression on antiretroviral treatment

While adolescents and young adults are about as likely as older people to be linked to care after being diagnosed with HIV in the United States,

Published
13 hours ago
By
Liz Highleyman
Botswana prisons: Foreign inmates win case for free HIV treatment

Botswana's court of appeal has upheld a ruling that foreign prisoners should receive free treatment for HIV/Aids, rights lawyers say.

Published
15 hours ago
From
BBC
One in four hepatitis C patients denied initial approval for drug treatment

This study adds to a growing body of literature on the hepatitis C “cascade of care,” in which attrition occurs at every step from diagnosis, confirmation, linkage to care, and treatment.

Published
15 hours ago
From
Yale News
Health and Wellbeing Board priorities and good practice across England

By selecting a single area on the map you can view a summary of the local priorities, and access links to the Health and Wellbeing Strategy and reports highlighting measures of health and wellbeing for that area, as well as examples of good practice known in the area.

Published
15 hours ago
From
Local Government Association
Gilead applies for PrEP approval in Canada

Gilead has applied to Health Canada for Truvada to be approved as PrEP – HIV pre-exposure prophylaxis. Truvada is not approved as PrEP yet in Canada which means doctors must prescribe it off-label and it is not yet on any provincial drug plan formularies outside of Quebec. Gilead Pharmaceuticals has now formally submitted its application to Health Canada for Truvada to also be approved for a preventative indication. Much of this can be attributed to a petition launched in April by several HIV and gay men’s health organizations in Canada, calling on Gilead to apply to Health Canada.

Published
27 August 2015
From
Homoculture.ca
Human rights groups face global crackdown 'not seen in a generation'

Laws affecting funding, requiring registration and prohibiting protest are among controls that are making it difficult for NGOs and other campaign groups.

Published
27 August 2015
From
The Guardian
White House Is Pressed to Help Widen Access to Hepatitis C Drugs via Medicaid

The advisory council criticized three types of restrictions. Some states cover the new drugs only for patients who have advanced liver disease. Many states require patients to abstain from the use of alcohol or illicit drugs for up to a year before treatment. And some states will not cover the drugs unless they are prescribed by specialists like gastroenterologists or experts on infectious diseases.

Published
26 August 2015
From
New York Times
Can we ensure adherence to STI treatment guidelines in a world threatened by antimicrobial resistance?

Sexual health care in the UK has traditionally centred on specialist GUM (genito-urinary medicine) services. Since the turn of the twenty-first century primary care has played an increasing role, however. The 2012 Health and Social Care Act is in line with this tendency, with most GP practices now being commissioned to provide level 1 STI screening. Questions have recently been raised about the conformity of care provided by GPs to national guidelines, established for the UK by the British Association for Sexual Health and HIV. In a world where Gonorrhoea – and perhaps one day Chlamydia – is set to become increasingly hard to treat, the problem of ensuring the conformity of generalists to universal standards of treatment is unlikely to go away.

Published
26 August 2015
From
BMJ
Hepatitis C treatment: Back to the warehouse

Like many physicians that specialize in hepatitis C virus (HCV) treatment, I have spent the last few years advising many of my patients with chronic HCV infection to defer treatment and wait for new therapies. Patients, advocacy groups, and physicians closely followed the development of [these new therapies] in eager anticipation of US Food and Drug Administration (FDA) approval and, for most patients, the possibility of a cure of their HCV infection. However, this eager anticipation morphed into uneasy concern as, along with FDA approval, drug pricing was announced.

Published
26 August 2015
From
Clinical Liver Disease
← First12345...497Next →

Filter by country